STA
RPRX icon

Summit Trail Advisors’s Royalty Pharma RPRX Stock Holding History

Summit Trail Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
39,362
+5,751
+17% +$299K 0.03% 549
2026
Q1 		$1.61M Buy
33,611
+942
+3% +$41.3K 0.02% 686
2025
Q4 		$1.26M Sell
32,669
-3,098
-9% -$118K 0.02% 681
2025
Q3 		$1.26M Buy
35,767
+28,463
+390% +$1.03M 0.02% 701
2025
Q2 		$263K Buy
+7,304
New +$242K ﹤0.01% 972

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Trail Advisors's RPRX Position: Q2 2026 in Review

Summit Trail Advisors increased its Royalty Pharma (RPRX) stake by 17% in Q2 2026, buying an estimated $299K and bringing the position to 39,362 shares worth $2.21M. The position accounts for 0.03% of the portfolio, ranked #549.

Summit Trail Advisors first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Summit Trail Advisors held 39,362 shares of Royalty Pharma worth $2.21M as of Q2 2026.
  • Summit Trail Advisors bought 5,751 Royalty Pharma shares in Q2 2026, an estimated $299K.
  • Royalty Pharma made up 0.03% of Summit Trail Advisors's portfolio in Q2 2026, its #549 holding.
  • Summit Trail Advisors first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.